Clinical trial NCT00705549 (phase 2, status: terminated)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gemcitabine, cisplatin, docetaxel, cisplatin, vinorelbine, pemetrexate
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically proven Stage IV and Stage III (with malignant pleural or
             pericardial effusion) squamous or adenocarcinoma carcinomas of the lung

          -  Adequate Formalin Fixed Paraffin Embedded tumor sample provided for molecular analysis

          -  No previous anticancer treatment for metastatic/advanced disease. Patients who
             received prior adjuvant chemotherapy are eligible if they have remained free of
             disease for at least 6 months after the completion of adjuvant therapy.

          -  Age above 18 years

          -  Performance status (ECOG) 0-2

          -  Life expectancy >= 3 months

          -  Effective contraception for both male and female subjects if the risk of conception
             exists

          -  Adequate hematologic parameters (absolute neutrophil count >= 1.5x109/L and platelets
             >= 100x109/L), creatinine (GFR>= 60ml/min) and total bilirubin < 1.5 times the upper
             limit of normal; aspartate and alanine aminotransferase < 2,5 times the upper limit of
             normal

          -  All patients will have to sign written informed consent in order to participate in the
             study

        Exclusion Criteria:

          -  Patients with non-squamous tumors who have no contradiction for administration of
             bevacizumab

          -  Active infection or malnutrition (loss of more than 20% of the body weight)

          -  Known hypersensitivity reaction to any of the component of the treatment

          -  Concurrent or previous chronic systemic immune therapy

          -  Pregnancy (absence to be confirmed by ß-HCG test) or lactation period

          -  Known alcohol/drug abuse

          -  Legal incapacity or limited legal capacity

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the subject to complete the study or sign meaningful informed consent

          -  A second primary tumor other than non-melanoma skin cancer or in situ cervical
             carcinoma

          -  Previous radiotherapy to the target lesions. Patients treated with palliative
             radiotherapy had to have measurable metastatic disease outside the irradiation fields

          -  Patients with severe cardiac dysfunction, unstable angina petrosis, or high risk of
             uncontrolled arrhythmia